BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 56,705 shares of the biopharmaceutical company’s stock after buying an additional 3,496 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned about 0.05% of Regeneron Pharmaceuticals worth $25,354,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC grew its position in Regeneron Pharmaceuticals by 2,132.8% in the 2nd quarter. Acadian Asset Management LLC now owns 1,496 shares of the biopharmaceutical company’s stock valued at $735,000 after purchasing an additional 1,429 shares during the period. Korea Investment CORP grew its position in Regeneron Pharmaceuticals by 7,615.1% in the 2nd quarter. Korea Investment CORP now owns 22,991 shares of the biopharmaceutical company’s stock valued at $11,292,000 after purchasing an additional 22,693 shares during the period. IFP Advisors Inc grew its position in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 96 shares during the period. HL Financial Services LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $669,000. Finally, Global X Management Co. LLC grew its position in Regeneron Pharmaceuticals by 43.8% in the 2nd quarter. Global X Management Co. LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 367 shares during the period. 66.67% of the stock is owned by institutional investors.

Several analysts recently issued reports on REGN shares. Zacks Investment Research downgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Jefferies Group restated a “hold” rating and set a $500.00 price objective (up from $471.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, September 29th. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 31st. Finally, Evercore ISI dropped their price objective on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a research note on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $467.84.

In other news, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at $4,950,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $375.13 on Thursday. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $40,003.84, a PE ratio of 32.24, a price-to-earnings-growth ratio of 1.46 and a beta of 1.53. Regeneron Pharmaceuticals, Inc. has a twelve month low of $340.09 and a twelve month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same quarter in the previous year, the firm earned $3.13 earnings per share. Regeneron Pharmaceuticals’s revenue was up 23.0% on a year-over-year basis. equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/07/regeneron-pharmaceuticals-inc-regn-holdings-increased-by-british-columbia-investment-management-corp.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.